Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Journal of Pharmaceutical Research International ; 33(57B):178-188, 2021.
Article in English | Web of Science | ID: covidwho-1614276


COVID-19 patients have lower immunosuppressive CD4+ T and CD8+ T cells and henceforth patients in intensive care units (ICU) need mechanical ventilation, henceforward they stay in hospitals. These patients have been exposed to advances in fungal co-infections. COVID-19 patients progress towards mucormycosis a black fungal infection that is deadly leading to loss of sight and hearing and eventually death. This article discusses the clinical manifestations, risk factors and emphases on virulence traits and management of black fungus.

Journal of Clinical and Diagnostic Research ; 15(8):QD01-QD02, 2021.
Article in English | EMBASE | ID: covidwho-1377111


The effects of Severe Acute Respiratory Distress Syndrome-Associated Coronavirus-2 (SARS-CoV-2) on the placental tissue are still being explored. Whether these placental changes result in adverse fetomaternal outcome is an aspect that needs to be understood. This is a report of 32-year-old pregnant woman who presented with Antepartum Haemorrhage (APH) and decreased fetal movements. She was also diagnosed to be positive for the SARS-CoV-2. The patient had abruptio placentae unrelated to preeclampsia. On histopathological examination, the umbilical cord showed funisitis with increased perivillous fibrin deposition on section from foetal and maternal surface of the placenta. Though the foetus was stillborn, with timely management the maternal outcome was not compromised.

Bjog-an International Journal of Obstetrics and Gynaecology ; 128:210-210, 2021.
Article in English | Web of Science | ID: covidwho-1268973
Med Hypotheses ; 144: 110133, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-670653


COVID-19 is an overwhelming pandemic which has shattered the whole world. Lung injury being the main clinical manifestation, it is likely to cause COPD (chronic obstructive pulmonary disease) and ARDS (acute respiratory distress syndrome). The possible cause behind this might be redox imbalance due to viral infection. Elevation in Glutathione (GSH) levels by administration of its promolecule might be effective. N-acetylcysteine is one such drug with potency to scavenge Reactive Oxygen Species, least side effects, and an effective precursor of glutathione. Consequently we hypothesize that N-acetylcysteine along with the conventional treatment may be treated as a potential therapeutic solution in cases of COVID-19 patients.

Acetylcysteine/therapeutic use , Glutathione/metabolism , Acetylcysteine/chemistry , Antioxidants/therapeutic use , Humans , Oxidation-Reduction , Oxidative Stress , Pulmonary Disease, Chronic Obstructive/virology , Reactive Oxygen Species/metabolism , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/virology